25

25 1 d879599d25.htm 25 25


		OMB APPROVAL
		OMB Number:		3235-0080
		Expires:		May 31, 2027
		Estimated average burden hours per response:		1.00

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING

AND/OR REGISTRATION UNDER SECTION 12(b)

OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number 001-40227

Finch Therapeutics Group, Inc.

The Nasdaq Global Select Market

(Exact name of Issuer as specified in its charter, and name of Exchange

where security is listed and/or registered)

75 State Street, Suite 100

Boston, MA 02109 (617) 229-6499

(Address, including zip code, and telephone number, including area code, of Issuer’s principal executive offices)

Common Stock, $0.001 par value per share

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

☐

17 CFR 240.12d2-2(a)(1)

☐

17 CFR 240.12d2-2(a)(2)

☐

17 CFR 240.12d2-2(a)(3)

☐

17 CFR 240.12d2-2(a)(4)

☐

Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange.¹

☒

Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with the rules of the Exchange and the requirements of 17 CFR 240.12d2-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements of the Securities Exchange Act of 1934, Finch Therapeutics Group, Inc. certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.


October 31, 2024	By:	/s/ Matthew P. Blischak	Chief Executive Officer
Date	Name:	Matthew P. Blischak	Title

¹	Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.


SEC 1654 (03-06)		Potential persons who are to respond to the collection of information contained in this Form are not required to respond unless the Form displays a currently valid OMB control number.

SEC Form 25 filed by Finch Therapeutics Group Inc.